Apraglutide: complete guide

Apraglutide is a long-acting GLP-2 analog in phase 3 for short bowel syndrome. Its STARS trial met its primary endpoint, and a confirmatory trial is now recruiting.

Complete guide5 min read

Key takeaway

In the STARS phase 3 trial, weekly parenteral support volume fell 25.5% with apraglutide and 12.5% with placebo at week 24 (P = .001). In rats, its elimination half-life was 159 minutes, compared with 19 minutes for teduglutide. FDA designated it an orphan drug for short bowel syndrome on December 20, 2018.

At a glance

Article typeComplete guide
Regulatory statusIn clinical trials“Apraglutide is not approved by the FDA for any use.” (this article)
ClassGut & digestion
Body systemsGut
Studies cited4 in this article · 4 across 1 article on Apraglutide
Related productsResearch peptide catalog

Apraglutide is a long-acting synthetic analog of the gut hormone glucagon-like peptide-2 (GLP-2). It is in development for short bowel syndrome with intestinal failure. A phase 3 trial met its primary endpoint, but the developer says a second, confirmatory phase 3 trial is needed. Sources were checked on November 17, 2026.

Quick answer: Apraglutide is an investigational GLP-2 analog, not an approved drug. In April 2025, Ironwood Pharmaceuticals said a confirmatory phase 3 trial is needed to seek approval. It cited drug exposure in STARS that was lower than planned. That trial, STARS-2, is listed as recruiting.

Vitrapep does not sell apraglutide; this page is a reference summary of published research and regulatory information.

What is apraglutide?

Apraglutide is a synthetic peptide modeled on human GLP-2, which is a 33-amino-acid hormone (Hargrove et al., 2020). It was first studied under the code FE 203799 (Slim et al., 2019). PubChem’s record for FE 203799 gives the formula C172H263N43O52 and a molecular weight of 3,765 g/mol (PubChem CID 155559189).

It counts as a peptide because it is a chain of amino acids built on a natural peptide hormone. Its main design goal is a longer time in the body than GLP-2 or earlier analogs. Our guide to peptide half-life explains why that matters. The closest approved relative is covered in our teduglutide guide.

Table 1

Apraglutide: key facts

Fact Detail
Structure type Synthetic peptide analog of GLP-2
Class Long-acting GLP-2 receptor agonist (investigational)
Molecular formula C172H263N43O52 (PubChem, listed as FE 203799)
Molecular weight 3,765 g/mol
Development stage Phase 3: STARS completed 2024; confirmatory STARS-2 recruiting (2026)
Sponsor or developer VectivBio AG (registry sponsor); Ironwood Pharmaceuticals (FDA orphan designation sponsor)

How does apraglutide work?

Apraglutide activates the GLP-2 receptor. In laboratory tests it kept potency and selectivity at that receptor comparable to native human GLP-2 (Hargrove et al., 2020). Its distinguishing feature is slow clearance. In rats, its elimination half-life was 159 minutes. That compares with 19 minutes for teduglutide, 16 minutes for glepaglutide and 6.4 minutes for native GLP-2. Monkey and minipig studies confirmed the long-acting profile.

The aim is to help the remaining intestine absorb more fluid and nutrients. In neonatal piglets with short bowel syndrome, apraglutide reduced fecal fat and energy loss. It also increased intestinal length, small-intestinal weight and villus height compared with saline (Slim et al., 2019). These are animal data.

What is apraglutide being studied for?

Apraglutide is not approved by the FDA for any use. Its main target is short bowel syndrome with intestinal failure (SBS-IF) in patients who depend on parenteral support. Parenteral support means nutrition and fluids that bypass the gut. ClinicalTrials.gov lists these patient studies, all sponsored by VectivBio AG:

  • STARS, phase 3, SBS-IF, 164 enrolled, completed February 2024 (NCT04627025);
  • STARS Extend, phase 3 open-label extension, 158 enrolled, active and not recruiting (NCT05018286);
  • STARS-2, phase 3, randomized, placebo-controlled, about 124 adults, recruiting (NCT07742735); and
  • acute graft-versus-host disease, phase 2, 31 enrolled, terminated for a “company decision” (NCT05415410).

Smaller completed studies covered kidney and liver impairment, gastric emptying and intestinal absorption. STARS-2 uses the same primary outcome as STARS: relative change in weekly parenteral support volume at week 24.

What did the key trials show?

STARS, phase 3. This global, double-blind, placebo-controlled trial randomized patients 2 to 1 to apraglutide or placebo. Randomization was stratified by remaining bowel anatomy: a stoma or colon-in-continuity. In total, 163 patients were randomized and treated: 80 with a stoma and 83 with colon-in-continuity (Joly et al., 2026).

At week 24, weekly parenteral support volume fell 25.5% with apraglutide and 12.5% with placebo (P = .001). In the stoma group, the figures were 25.6% and 7.8% (P < .001). A reduction of at least one day a week of parenteral support was seen in 43.0% vs 27.5% (P = .040). In the colon-in-continuity group at week 48, that one-day reduction did not differ significantly (51.8% vs 44.4%, P = .348).

In April 2025, Ironwood said drug exposure in STARS was “lower than planned.” It concluded “a confirmatory Phase 3 trial is needed to seek approval” (Ironwood, 2025).

Phase 2. A randomized, double-blind, placebo-controlled crossover trial enrolled 8 adults with SBS-IF. Its primary endpoint was safety. Urine volume rose versus placebo, by adjusted means of 714 to 795 mL/day. The authors read this as better intestinal fluid absorption (Eliasson et al., 2022). Both trials were in humans.

What side effects have studies reported?

In the small phase 2 trial, the most common treatment-related adverse events were mild to moderate (Eliasson et al., 2022):

  • polyuria (passing more urine);
  • decreased stoma output and stoma complications;
  • decreased thirst; and
  • edema (swelling).

No serious adverse events were judged related to apraglutide in that trial. The STARS authors wrote that apraglutide “was well-tolerated with a favorable safety profile.” Its abstract did not list event rates, and the STARS registry record has no posted results.

What is apraglutide’s regulatory status, and how is it used in research?

Apraglutide is an investigational drug in the United States. FDA designated it an orphan drug for “Treatment of short bowel syndrome (SBS)” on December 20, 2018. The listed sponsor is Ironwood Pharmaceuticals, and the status is “Not FDA Approved for Orphan Indication” (FDA orphan database). Orphan designation is not an approval.

In its April 2025 release, Ironwood also said it had engaged Goldman Sachs to explore strategic alternatives for the company. In research, apraglutide has been studied in piglet and rat models of intestinal growth. For the related GLP-2 drugs, see our teduglutide and glepaglutide guides.

Frequently asked questions about apraglutide

Is apraglutide a peptide?

Yes. It is a synthetic peptide analog of GLP-2, a 33-amino-acid gut hormone.

Is apraglutide FDA approved?

No. It holds an FDA orphan designation for short bowel syndrome, and a confirmatory phase 3 trial is recruiting.

How is apraglutide different from teduglutide?

Both act on the GLP-2 receptor. In rats, apraglutide’s elimination half-life was 159 minutes versus 19 minutes for teduglutide.

What did the STARS trial show?

At week 24, weekly parenteral support volume fell 25.5% with apraglutide and 12.5% with placebo (P = .001).

Why is another phase 3 trial needed?

Ironwood said drug exposure in STARS was lower than planned. It said a confirmatory phase 3 trial is needed to seek approval.

What to know now

  • Structure: synthetic GLP-2 analog; 3,765 g/mol (as FE 203799).
  • Mechanism: GLP-2 receptor agonist with slow clearance (rat half-life 159 minutes).
  • Evidence: STARS phase 3 cut parenteral support volume 25.5% vs 12.5%.
  • Status: not FDA-approved; orphan designation for short bowel syndrome since 2018.
  • Next: confirmatory STARS-2 trial, about 124 adults, recruiting.
  • Safety: phase 2 events mostly mild to moderate; no related serious events.

What we’re watching

Enrollment and results of STARS-2, with primary completion estimated for October 2028. Completion of the STARS Extend safety study, estimated for October 2027. Related guides: glepaglutide, teduglutide and larazotide acetate.

More for gut

All 11 compounds for gut

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 155559189, FE 203799; Hargrove 2020, Journal of Pharmacology and Experimental Therapeutics, 373; Slim 2019, JPEN Journal of Parenteral and Enteral Nutrition, 43; Joly 2026, Clinical Gastroenterology and Hepatology; Eliasson 2022, JPEN Journal of Parenteral and Enteral Nutrition, 46; Ironwood Pharmaceuticals 2025, Ironwood Pharmaceuticals provides clinical and regulatory update on apraglutide; U.S. Food and Drug Administration. Search orphan drug designations and approvals: apraglutide (designated 12/20/2018). Retrieved November 17, Search orphan drug designations and approvals: apraglutide; VectivBio AG 2020, Trial to evaluate efficacy and safety of apraglutide in SBS-IF (STARS); VectivBio AG 2026; VectivBio AG 2021; VectivBio AG 2022, Proof-of-concept trial of apraglutide in acute graft versus host disease (aGVHD). All 11 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 155559189, FE 203799. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/155559189
  2. Hargrove, D. M., Alagarsamy, S., Croston, G., et al. (2020). Pharmacological characterization of apraglutide, a novel long-acting peptidic glucagon-like peptide-2 agonist, for the treatment of short bowel syndrome. Journal of Pharmacology and Experimental Therapeutics, 373(2), 193-203. https://doi.org/10.1124/jpet.119.262238
  3. Slim, G. M., Lansing, M., Wizzard, P., et al. (2019). Novel long-acting GLP-2 analogue, FE 203799 (apraglutide), enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum. JPEN Journal of Parenteral and Enteral Nutrition, 43(7), 891-898. https://doi.org/10.1002/jpen.1500
  4. Joly, F., Vanuytsel, T., Kirby, D. F., et al. (2026). STARS phase 3 trial: Once-weekly apraglutide reduces parenteral support in short bowel syndrome-intestinal failure. Clinical Gastroenterology and Hepatology. Advance online publication. https://doi.org/10.1016/j.cgh.2026.08.026
  5. Eliasson, J., Hvistendahl, M. K., Freund, N., et al. (2022). Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial. JPEN Journal of Parenteral and Enteral Nutrition, 46(4), 896-904. https://doi.org/10.1002/jpen.2223
  6. Ironwood Pharmaceuticals. (2025, April 14). Ironwood Pharmaceuticals provides clinical and regulatory update on apraglutide [Press release, Form 8-K exhibit 99.1]. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1446847/000110465925034381/tm2512215d1_ex99-1.htm
  7. U.S. Food and Drug Administration. Search orphan drug designations and approvals: apraglutide (designated 12/20/2018). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=639518
  8. VectivBio AG. (2020). Trial to evaluate efficacy and safety of apraglutide in SBS-IF (STARS) (ClinicalTrials.gov ID NCT04627025). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT04627025
  9. VectivBio AG. (2026). A study to investigate the efficacy and safety of apraglutide compared with placebo in adult participants with short bowel syndrome associated with intestinal failure (STARS-2) (ClinicalTrials.gov ID NCT07742735). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT07742735
  10. VectivBio AG. (2021). Open-label extension trial to evaluate the long-term safety of apraglutide in short bowel syndrome (STARS Extend) (ClinicalTrials.gov ID NCT05018286). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05018286
  11. VectivBio AG. (2022). Proof-of-concept trial of apraglutide in acute graft versus host disease (aGVHD) (ClinicalTrials.gov ID NCT05415410). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT05415410